Angle plc (AGL) Ordinary 10p
1.50p
(2.19%)
- Add to watchlist
- Create an alert
- This stock can be held in a
1.50p
(2.19%)
1.50p
(2.19%)
Share news, reports & tips
-
Angle looks to strengthen balance sheet and extend runway via placement
25 June 2019 08:16
(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of...
-
Angle upbeat on recent cancer research results
21 June 2019 15:26
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its...
-
Angle reveals positive results from latest Parsortix study
31 May 2019 09:53
(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.
-
Angle's Parsortix system used in more groundbreaking research
26 April 2019 12:48
(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of...
-
Angle's Parsortix to be used in new Greece study
12 April 2019 15:25
(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its...
-
Angle completes enrolment in Parsortix breast cancer study
7 March 2019 09:35
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.
-
Angle client demonstrates new use for 'Parsortix' system
25 February 2019 10:51
(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed...
-
Angle's 'Parsortix' used in new groundbreaking cancer research
11 February 2019 11:35
(Sharecast News) - Liquid biopsy company Angle announced on Monday that its 'Parsortix' system had been utilised in further "groundbreaking" cancer research into CTC clusters, reportedly...
-
Angle sees 'highly encouraging' results from prenatal testing
29 October 2018 11:08
(Sharecast News) - Medical diagnostics outfit Angle is talking to "several interested parties" to commercialise its testing device after a "highly encouraging" trial indicated it could be...
-
Angle makes 'good progress' with ANG-002 patient enrolment
25 October 2018 08:52
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that patient enrolment for its ANG-002 FDA clinical study for metastatic breast cancer had continued to make good progress.
-
Angle optimises first ever workflow to culture CTCs
19 April 2018 10:47
(ShareCast News) - AIM-quoted liquid biopsy company Angle has demonstrated a workflow for culturing circulating tumour cells using its Parsortix system.
-
Angle PMT test out-performs in diagnosing ovarian cancer
26 March 2018 08:11
(ShareCast News) - A blood test for ovarian cancer by UK medical technology company Angle has achieved a 95.1% correct prediction of cancer.
Company announcements Announcements
-
Holding(s) in Company
16 July 2019 09:19
Angle
-
Result of General Meeting anf Total Voting Rights
12 July 2019 10:22
Angle
-
Notice of Preliminary Results and Webcast
28 June 2019 13:37
Angle
-
Holding(s) in Company
28 June 2019 13:08
Angle
-
Result of Placing
25 June 2019 17:19
Angle
-
Accelerated bookbuild to raise £18.0m
25 June 2019 08:02
Angle
-
Parsortix used to investigate immunotherapy target
21 June 2019 07:00
Angle
-
Completion of Ovarian Cancer Pre-Study
5 June 2019 07:00
Angle
-
Positive Results from FDA Clinical Study
31 May 2019 07:00
Angle
-
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
26 April 2019 07:00
Angle
-
Parsortix used in new cancer assessment technique
18 April 2019 07:00
Angle
-
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
12 April 2019 07:00
Angle
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2019. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.